- Home
- JAZZ vs SRPT Comparison
JAZZ vs SRPT Comparison
Compare JAZZ & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- SRPT
- Stock Information
- Founded
- JAZZ 2003
- SRPT 1980
- Country
- JAZZ Ireland
- SRPT United States
- Employees
- JAZZ N/A
- SRPT N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- SRPT Biotechnology: Pharmaceutical Preparations
- Sector
- JAZZ Health Care
- SRPT Health Care
- Exchange
- JAZZ Nasdaq
- SRPT Nasdaq
- Market Cap
- JAZZ 8.4B
- SRPT 9.8B
- IPO Year
- JAZZ 2007
- SRPT 1997
- Fundamental
- Price
- JAZZ $122.92
- SRPT $70.41
- Analyst Decision
- JAZZ Strong Buy
- SRPT Buy
- Analyst Count
- JAZZ 13
- SRPT 21
- Target Price
- JAZZ $187.15
- SRPT $164.05
- AVG Volume (30 Days)
- JAZZ 1.3M
- SRPT 2.2M
- Earning Date
- JAZZ 04-30-2025
- SRPT 04-30-2025
- Dividend Yield
- JAZZ N/A
- SRPT N/A
- EPS Growth
- JAZZ 41.75
- SRPT N/A
- EPS
- JAZZ 8.65
- SRPT 2.34
- Revenue
- JAZZ $4,068,950,000.00
- SRPT $1,901,979,000.00
- Revenue This Year
- JAZZ $7.30
- SRPT $67.83
- Revenue Next Year
- JAZZ $4.01
- SRPT $25.66
- P/E Ratio
- JAZZ $14.21
- SRPT $30.11
- Revenue Growth
- JAZZ 6.12
- SRPT 52.97
- 52 Week Low
- JAZZ $99.06
- SRPT $69.82
- 52 Week High
- JAZZ $148.06
- SRPT $173.25
- Technical
- Relative Strength Index (RSI)
- JAZZ 32.69
- SRPT 27.35
- Support Level
- JAZZ $137.74
- SRPT $70.91
- Resistance Level
- JAZZ $142.64
- SRPT $76.67
- Average True Range (ATR)
- JAZZ 3.87
- SRPT 4.14
- MACD
- JAZZ -2.12
- SRPT -1.57
- Stochastic Oscillator
- JAZZ 0.45
- SRPT 1.78
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.